Moscow, November 21, 2012 -O JSC Pharmstandard announces the acquisition of 100% stake in «LEKKO» CJSC.

On September 6, 2012 Russia’s Federal Antimonopoly Service (FAS) has granted approval for OJSC Pharmstandard’s bid to acquire 100% of the voting shares of CJSC «LEKKO».

«LEKKO» CJSC is a Russian innovative company which performs in the field of research and development of highly effective drugs as well as their production and distribution. The company has an 18-year track record of successful market presence and it’s products are a result of years of successful investments into promising scientific researches in the field of traditional medicine.

«LEKKO» CJSC production facilities are located in Volginsky village (Vladimir region). Annual output amounts to 50 million packs of 11 pharmaceutical products. The company employs 400 highly-qualified professionals in the field of medicine and pharmacy, biology and chemistry, management, marketing and technology.

«LEKKO» CJSC 2011 audited revenues amounted to RUR684.4m. 3Q2012 revenues reached RUR357.6m.

Pharmstandard OJSC uses LEKKO facilities to produce Rinostop^® and Acipol^®. 3Q2012 sales of these drugs amounted to RUR111.6m and RUR266.04m accordingly.

Pharmstandard OJSC management believes that the acquisition of LEKKO is highly effective for further successful production of Rinostop^® and Acipol^® as well as for the expansion of business in general.

Irina Bakhturina
Investor Relations
OJSC Pharmstandard
+7 495 970 00 30 ext.2824
www.pharmstd.com